CRIS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRIS is not a good buy right now for a beginner long-term investor with $50,000-$100,000. The stock is extremely weak on fundamentals, is trading in a bearish trend, and lacks a clear high-conviction buy signal from the proprietary tools. The only supportive factors are its oncology pipeline and FDA orphan drug designations, but those are not enough to outweigh the sharp revenue decline and overall weak trading setup. For an impatient investor who does not want to wait for a better entry, this is still not an attractive entry today.
The technical picture is bearish overall. Price is 0.5925 after a -6.45% regular-session drop, which shows immediate weakness despite a small post-market bounce. RSI_6 at 45 is neutral, so there is no strong momentum reversal yet. MACD histogram is slightly positive but contracting, which suggests fading upside momentum. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the stock remains in a downtrend. Key levels to watch are pivot 0.58, resistance at 0.617 and 0.639, and support at 0.544 and 0.521. The technical setup does not support an aggressive long-term buy right now.
Curis is advancing the TakeAim Lymphoma Phase 1/2 study for emavusertib in relapsed/refractory primary central nervous system lymphoma. Emavusertib also has FDA Orphan Drug Designation for PCNSL, AML, and MDS, which is a meaningful pipeline catalyst and can support longer-term sentiment if clinical progress continues. The company is also reporting Q1 2026 earnings, which could provide a near-term update and catalyst if results or guidance improve.
Latest financials are weak, with Q4 2025 revenue down 65.98% YoY to 1.138 million, net income down 301.25% YoY, and EPS down 198.40% YoY. The stock also fell sharply in the regular session, showing poor market confidence. Hedge funds and insiders are both neutral with no significant recent trading trends. There is no recent congress trading data. Analyst sentiment data was not provided, but the available fundamentals and price action do not suggest a strong Wall Street bullish consensus.
In Q4 2025, Curis posted declining operating performance: revenue fell 65.98% YoY to 1.138 million, gross margin slipped to 72.41%, and EPS deteriorated sharply to 1.23 from the prior year comparison. Net income also dropped significantly, showing that the latest quarter season was materially weaker year over year. Overall, the quarter reflects contracting business activity rather than growth.
No specific analyst rating or price target change data was provided. Based on the available information, Wall Street pros would likely be split to negative: the bull case is the oncology pipeline and orphan-drug status, while the bear case is the steep revenue decline, weak earnings trend, and bearish price structure. Without visible upgrades or rising targets, the analyst picture does not support a strong buy.
